{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-096572","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.944723+00:00","generated_at":"2026-06-11T02:12:54.072542+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Eloxx Pharma Board approves retention program with performance-based equity grants to CEO","bullets":["CEO Sumit Aggarwal granted 75,000 performance RSUs and 25,000 performance stock options (exercise price $4.63).","Awards vest upon earliest of: $35M market cap, $25M capital raise, or change in control.","Future grants of 60,000 RSUs to CEO and 20,000 RSUs to Head of R&D Vijay Modur, subject to share availability.","Additional 50,000 stock option for CEO under same condition, with exercise price not greater than $4.63."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-096572","json":"https://secwatch.observer/filing/0001104659-23-096572.json","markdown":"https://secwatch.observer/filing/0001104659-23-096572.md","text":"https://secwatch.observer/filing/0001104659-23-096572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923096572/0001104659-23-096572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923096572/tm2325066d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:12:54.072542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}